Document is current
Any future updates will be listed below
-
Authors
Snyder, Edward L.
Sekela, Michael E.
Welsby, Ian J.
Toyoda, Yoshiya
Alsammak, Mohamed
Sodha, Neel R.
Beaver, Thomas M.
Pelletier, J. Peter R.
Gorham, James D.
McNeil, John S.
Sniecinski, Roman M.
Pearl, Ronald G.
Nuttall, Gregory A.
Sarode, Ravi
Reece, T. Brett
Kaplan, Alesia
Davenport, Robertson D.
Ipe, Tina S.
Benharash, Peyman
Lopez-Plaza, Ileana
Gammon, Richard R.
Sadler, Patrick
Pitman, John P.
Liu, Kathy
Bentow, Stanley
Corash, Laurence
Mufti, Nina
Varrone, Jeanne
Benjamin, Richard J. http://orcid.org/0000-0001-6618-4744
,
-
Funding
Funding for this research was provided by:
Biomedical Advanced Research and Development Authority (HHS010020160009c)
- License Information
-
More Information
Article History
Received: 19 September 2023
Accepted: 24 November 2023
First Online: 11 December 2023
Declarations
:
: The ReCePI study (CLI 00125 v8.0) has been approved by the WCG IRB, most recently on 23 May 2023 (IRB Tracking Number: 20181561) and by multiple institutional review boards. Written, informed consent to participate will be obtained from all participants.
: Informed consent is obtained for publication of anonymized patient data at the time of patient consent for enrollment.
: RJB, KL, SB, JPP, NM, LC, and JV are employees and shareholders of Cerus Corporation equity, the Sponsor of the study. The investigators are independent of the Sponsor and declare no relevant conflict of interest. ELS, MES, IJW, YT, NRS, TMB, JPRP, JDG, JSM, RMS, RGP, GAN, RS, TBR, AK, RD, TS, PB, and IL-P are site investigators on the study, receive no compensation from the Sponsor and declare no conflicts relating to the study.
